Skip to main content
Erschienen in: Current Hepatology Reports 4/2016

27.10.2016 | Portal Hypertension (K Brown, Section Editor)

Possible Treatment Strategies for Portal Hypertension in Liver Cirrhosis

verfasst von: Robert Schierwagen, Frank Erhard Uschner, Sabine Klein, Jonel Trebicka

Erschienen in: Current Hepatology Reports | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose of the Review

Chronic liver injury leading to fibrosis and complicated by portal hypertension is an emerging burden for health systems worldwide, but current treatments are few and poorly effective. Therefore, this review aims to present diverse potential treatment approaches that are currently under investigation or on their way to clinical use.

Recent Findings

These options involve statins, the renin-angiotensin system and their downstream effectors, the anticoagulation system, farnesoid-x receptor agonism, and various other targets.

Summary

Since activated hepatic stellate cells play a pivotal role in both fibrogenesis and portal hypertension, most of these potential treatment approaches target directly or indirectly this profibrotic and procontractile cells in liver fibrosis with portal hypertension. Special focus should be paid to cell-specific treatments to minimize side effects and systemic complications in treatment of liver fibrosis and portal hypertension.
Literatur
2.
Zurück zum Zitat ••Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013;4:2823. This work demonstrates the prominent and pivotal role of activated hepatic stellate cells in liver fibrogenesis. ••Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013;4:2823. This work demonstrates the prominent and pivotal role of activated hepatic stellate cells in liver fibrogenesis.
3.
Zurück zum Zitat Baba TT, Ohara-Nemoto Y, Miyazaki T, Nemoto TK. Involvement of geranylgeranylation of Rho and Rac GTPases in adipogenic and RANKL expression, which was inhibited by simvastatin. Cell Biochem Funct. 2013;31:652–9.CrossRefPubMed Baba TT, Ohara-Nemoto Y, Miyazaki T, Nemoto TK. Involvement of geranylgeranylation of Rho and Rac GTPases in adipogenic and RANKL expression, which was inhibited by simvastatin. Cell Biochem Funct. 2013;31:652–9.CrossRefPubMed
4.
Zurück zum Zitat Veillard NR, Braunersreuther V, Arnaud C, Burger F, Pelli G, Steffens S, et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis. 2006;188:51–8.CrossRefPubMed Veillard NR, Braunersreuther V, Arnaud C, Burger F, Pelli G, Steffens S, et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis. 2006;188:51–8.CrossRefPubMed
5.
Zurück zum Zitat Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology. 2007;46:242–53.CrossRefPubMed Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology. 2007;46:242–53.CrossRefPubMed
6.
Zurück zum Zitat Trebicka J, Hennenberg M, Odenthal M, Shir K, Klein S, Granzow M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol. 2010;53:702–12.CrossRefPubMed Trebicka J, Hennenberg M, Odenthal M, Shir K, Klein S, Granzow M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol. 2010;53:702–12.CrossRefPubMed
7.
Zurück zum Zitat Klein S, Klösel J, Schierwagen R, Körner C, Granzow M, Huss S, et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab Investig. 2012;92:1440–50.CrossRefPubMed Klein S, Klösel J, Schierwagen R, Körner C, Granzow M, Huss S, et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab Investig. 2012;92:1440–50.CrossRefPubMed
8.
Zurück zum Zitat Schierwagen R, Leeming DJ, Klein S, Granzow M, Nielsen MJ, Sauerbruch T, et al. Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats. Front Physiol. 2013;4:195.CrossRefPubMedPubMedCentral Schierwagen R, Leeming DJ, Klein S, Granzow M, Nielsen MJ, Sauerbruch T, et al. Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats. Front Physiol. 2013;4:195.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat •Marrone G, Russo L, Rosado E, Hide D, García-Cardeña G, García-Pagán JC, et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol. 2013;58:98–103. An important work revealing that statins downregulate hepatic stellate cell activation by the intercellular communication between hepatic stellate cells and liver sinusoidal endothelial cells. •Marrone G, Russo L, Rosado E, Hide D, García-Cardeña G, García-Pagán JC, et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol. 2013;58:98–103. An important work revealing that statins downregulate hepatic stellate cell activation by the intercellular communication between hepatic stellate cells and liver sinusoidal endothelial cells.
10.
Zurück zum Zitat Abraldes JG, Rodríguez-Vilarrupla A, Graupera M, Zafra C, García-Calderó H, García-Pagán JC, et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol. 2007;46:1040–6.CrossRefPubMed Abraldes JG, Rodríguez-Vilarrupla A, Graupera M, Zafra C, García-Calderó H, García-Pagán JC, et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol. 2007;46:1040–6.CrossRefPubMed
11.
Zurück zum Zitat ••Marrone G, Maeso-Díaz R, García-Cardena G, Abraldes JG, García-Pagán JC, Bosch J, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut. 2015;64:1434–43. An important work that elucidates the molecular mechanisms how KLF2 effects liver fibrosis and portal hypertension. ••Marrone G, Maeso-Díaz R, García-Cardena G, Abraldes JG, García-Pagán JC, Bosch J, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut. 2015;64:1434–43. An important work that elucidates the molecular mechanisms how KLF2 effects liver fibrosis and portal hypertension.
12.
Zurück zum Zitat Trebicka J, Schierwagen R. Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension. Gut. 2015;64:1349–50.CrossRefPubMed Trebicka J, Schierwagen R. Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension. Gut. 2015;64:1349–50.CrossRefPubMed
13.
Zurück zum Zitat •Uschner FE, Ranabhat G, Choi SS, Granzow M, Klein S, Schierwagen R, et al. Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Sci Rep. 2015;5:14573. One of several important studies which clarifies how statins improve liver fibrosis and portal hypertension. •Uschner FE, Ranabhat G, Choi SS, Granzow M, Klein S, Schierwagen R, et al. Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Sci Rep. 2015;5:14573. One of several important studies which clarifies how statins improve liver fibrosis and portal hypertension.
14.
Zurück zum Zitat •Schierwagen R, Maybüchen L, Hittatiya K, Klein S, Uschner FE, Braga TT, et al. Statins improve NASH via inhibition of RhoA and Ras. Am J Physiol Gastrointest Liver Physiol. 2016; One of several important studies which clarifies how statins improve liver fibrosis in NASH. •Schierwagen R, Maybüchen L, Hittatiya K, Klein S, Uschner FE, Braga TT, et al. Statins improve NASH via inhibition of RhoA and Ras. Am J Physiol Gastrointest Liver Physiol. 2016; One of several important studies which clarifies how statins improve liver fibrosis in NASH.
15.
Zurück zum Zitat Park H-S, Jang JE, Ko MS, Woo SH, Kim BJ, Kim HS, et al. Statins increase mitochondrial and peroxisomal fatty acid oxidation in the liver and prevent non-alcoholic steatohepatitis in mice. Diabetes & Metabolism Journal [Internet]. 2016 (2016);40. Available from: /Synapse/10.4093/dmj.2016.40.e11 Park H-S, Jang JE, Ko MS, Woo SH, Kim BJ, Kim HS, et al. Statins increase mitochondrial and peroxisomal fatty acid oxidation in the liver and prevent non-alcoholic steatohepatitis in mice. Diabetes & Metabolism Journal [Internet]. 2016 (2016);40. Available from: /Synapse/10.​4093/​dmj.​2016.​40.​e11
16.
Zurück zum Zitat Chong L-W, Hsu Y-C, Lee T-F, Lin Y, Chiu Y-T, Yang K-C, et al. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells. BMC Gastroenterol. 2015;15:22.CrossRefPubMedPubMedCentral Chong L-W, Hsu Y-C, Lee T-F, Lin Y, Chiu Y-T, Yang K-C, et al. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells. BMC Gastroenterol. 2015;15:22.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Nascimbeni M, Perié L, Chorro L, Diocou S, Kreitmann L, Louis S, et al. Plasmacytoid dendritic cells accumulate in spleens from chronically HIV-infected patients but barely participate in interferon-alpha expression. Blood. 2009;113:6112–9.CrossRefPubMed Nascimbeni M, Perié L, Chorro L, Diocou S, Kreitmann L, Louis S, et al. Plasmacytoid dendritic cells accumulate in spleens from chronically HIV-infected patients but barely participate in interferon-alpha expression. Blood. 2009;113:6112–9.CrossRefPubMed
18.
Zurück zum Zitat Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63:705–12.CrossRefPubMed Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63:705–12.CrossRefPubMed
19.
Zurück zum Zitat Blais P, Lin M, Kramer JR, El-Serag HB, Kanwal F. Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. Dig Dis Sci. 2016;61:1714–20.CrossRefPubMed Blais P, Lin M, Kramer JR, El-Serag HB, Kanwal F. Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. Dig Dis Sci. 2016;61:1714–20.CrossRefPubMed
20.
Zurück zum Zitat Schierwagen R, Maybüchen L, Zimmer S, Hittatiya K, Bäck C, Klein S, et al. Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. Sci Rep. 2015;5:12931.CrossRefPubMedPubMedCentral Schierwagen R, Maybüchen L, Zimmer S, Hittatiya K, Bäck C, Klein S, et al. Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. Sci Rep. 2015;5:12931.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Oliver NT, Hartman CM, Kramer JR, Chiao EY. Statin drugs decrease progression to cirrhosis in HIV/HCV co-infected individuals. AIDS. 2016 Oliver NT, Hartman CM, Kramer JR, Chiao EY. Statin drugs decrease progression to cirrhosis in HIV/HCV co-infected individuals. AIDS. 2016
22.
Zurück zum Zitat Simon TG, King LY, Zheng H, Chung RT. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol. 2015;62:18–23.CrossRefPubMed Simon TG, King LY, Zheng H, Chung RT. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol. 2015;62:18–23.CrossRefPubMed
23.
Zurück zum Zitat Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology. 2016;64:47–57.CrossRefPubMed Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology. 2016;64:47–57.CrossRefPubMed
24.
Zurück zum Zitat Butt AA, Yan P, Bonilla H, Abou-Samra A-B, Shaikh OS, Simon TG, et al. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: results from ERCHIVES. Hepatology. 2015;62:365–74.CrossRefPubMed Butt AA, Yan P, Bonilla H, Abou-Samra A-B, Shaikh OS, Simon TG, et al. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: results from ERCHIVES. Hepatology. 2015;62:365–74.CrossRefPubMed
25.
Zurück zum Zitat Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García–Pagán JC, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136:1651–8.CrossRefPubMed Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García–Pagán JC, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136:1651–8.CrossRefPubMed
26.
Zurück zum Zitat ••Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology. 2016;150:1160–70.e3. An important work boostering the way of statins into clinics as a treatment option in liver fibrosis and portal hypertension. ••Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology. 2016;150:1160–70.e3. An important work boostering the way of statins into clinics as a treatment option in liver fibrosis and portal hypertension.
27.
Zurück zum Zitat Abraldes JG, Burak KW. STAT order: Should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma? Hepatology. 2016;64:13–5.CrossRefPubMed Abraldes JG, Burak KW. STAT order: Should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma? Hepatology. 2016;64:13–5.CrossRefPubMed
28.
Zurück zum Zitat ••Granzow M, Schierwagen R, Klein S, Kowallick B, Huss S, Linhart M, et al. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology. 2014;60:334–48. Important study outlining JAK2 as the effector of Arhgef1 and therefore as the link between AT1 receptor and RhoA/Rho-kinase signaling.CrossRefPubMed ••Granzow M, Schierwagen R, Klein S, Kowallick B, Huss S, Linhart M, et al. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology. 2014;60:334–48. Important study outlining JAK2 as the effector of Arhgef1 and therefore as the link between AT1 receptor and RhoA/Rho-kinase signaling.CrossRefPubMed
29.
Zurück zum Zitat Bataller R, Sancho-Bru P, Ginès P, Lora JM, Al-Garawi A, Solé M, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 2003;125:117–25.CrossRefPubMed Bataller R, Sancho-Bru P, Ginès P, Lora JM, Al-Garawi A, Solé M, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 2003;125:117–25.CrossRefPubMed
30.
Zurück zum Zitat Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology. 2002;123:1667–76.CrossRefPubMed Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology. 2002;123:1667–76.CrossRefPubMed
31.
Zurück zum Zitat Sumners C, Horiuchi M, Widdop RE, McCarthy C, Unger T, Steckelings UM. Protective arms of the renin-angiotensin-system in neurological disease. Clin Exp Pharmacol Physiol. 2013;40:580–8.CrossRefPubMed Sumners C, Horiuchi M, Widdop RE, McCarthy C, Unger T, Steckelings UM. Protective arms of the renin-angiotensin-system in neurological disease. Clin Exp Pharmacol Physiol. 2013;40:580–8.CrossRefPubMed
32.
Zurück zum Zitat Heller J, Shiozawa T, Trebicka J, Hennenberg M, Schepke M, Neef M, et al. Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats. Eur J Clin Investig. 2003;33:1006–12.CrossRef Heller J, Shiozawa T, Trebicka J, Hennenberg M, Schepke M, Neef M, et al. Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats. Eur J Clin Investig. 2003;33:1006–12.CrossRef
33.
Zurück zum Zitat Heller J, Trebicka J, Shiozawa T, Schepke M, Neef M, Hennenberg M, et al. Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. Liver Int. 2005;25:657–66.CrossRefPubMed Heller J, Trebicka J, Shiozawa T, Schepke M, Neef M, Hennenberg M, et al. Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. Liver Int. 2005;25:657–66.CrossRefPubMed
34.
Zurück zum Zitat Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology. 2001;121:389–95.CrossRefPubMed Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology. 2001;121:389–95.CrossRefPubMed
35.
Zurück zum Zitat Guilluy C, Brégeon J, Toumaniantz G, Rolli-Derkinderen M, Retailleau K, Loufrani L, et al. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med. 2010;16:183–90.CrossRefPubMed Guilluy C, Brégeon J, Toumaniantz G, Rolli-Derkinderen M, Retailleau K, Loufrani L, et al. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med. 2010;16:183–90.CrossRefPubMed
36.
Zurück zum Zitat ••Klein S, Rick J, Lehmann J, Schierwagen R, Schierwagen IG, Verbeke L, et al. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. Gut. 2015;gutjnl-2015-309600. An important work demonstrating the role of JAK2 signaling in portal hypertension with a strong translational focus. ••Klein S, Rick J, Lehmann J, Schierwagen R, Schierwagen IG, Verbeke L, et al. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. Gut. 2015;gutjnl-2015-309600. An important work demonstrating the role of JAK2 signaling in portal hypertension with a strong translational focus.
37.
Zurück zum Zitat Wang D, Yin J, Dong R, Zhao J, Wang Q, Wang N, et al. Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats. Dig Liver Dis. 2015;47:315–23.CrossRefPubMed Wang D, Yin J, Dong R, Zhao J, Wang Q, Wang N, et al. Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats. Dig Liver Dis. 2015;47:315–23.CrossRefPubMed
38.
Zurück zum Zitat Shaker ME, Hazem SH, Ashamallah SA. Inhibition of the JAK/STAT pathway by ruxolitinib ameliorates thioacetamide-induced hepatotoxicity. Food Chem. Toxicol. 2016 Shaker ME, Hazem SH, Ashamallah SA. Inhibition of the JAK/STAT pathway by ruxolitinib ameliorates thioacetamide-induced hepatotoxicity. Food Chem. Toxicol. 2016
39.
Zurück zum Zitat ••Grace JA, Klein S, Herath CB, Granzow M, Schierwagen R, Masing N, et al. Activation of the mas receptor by angiotensin-(1–7) in the renin–angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology. 2013;145:874–4.e5. An important work emphasizing the role of Mas receptor as the counterpart of the AT1 receptor in liver cirrhosis. ••Grace JA, Klein S, Herath CB, Granzow M, Schierwagen R, Masing N, et al. Activation of the mas receptor by angiotensin-(1–7) in the renin–angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology. 2013;145:874–4.e5. An important work emphasizing the role of Mas receptor as the counterpart of the AT1 receptor in liver cirrhosis.
40.
Zurück zum Zitat Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Update on new aspects of the renin–angiotensin system in liver disease: clinical implications and new therapeutic options. Clin Sci. 2012;123:225–39.CrossRefPubMed Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Update on new aspects of the renin–angiotensin system in liver disease: clinical implications and new therapeutic options. Clin Sci. 2012;123:225–39.CrossRefPubMed
41.
Zurück zum Zitat •Klein S, Herath CB, Schierwagen R, Grace J, Haltenhof T, Uschner FE, et al. Hemodynamic effects of the non-peptidic angiotensin-(1–7) agonist AVE0991 in liver cirrhosis. PLoS ONE. 2015;10:e0138732. One of several important works about the beneficial effects of Mas receptor stimulation in liver cirrhosis decreasing portal pressure without systemic effects.CrossRefPubMedPubMedCentral •Klein S, Herath CB, Schierwagen R, Grace J, Haltenhof T, Uschner FE, et al. Hemodynamic effects of the non-peptidic angiotensin-(1–7) agonist AVE0991 in liver cirrhosis. PLoS ONE. 2015;10:e0138732. One of several important works about the beneficial effects of Mas receptor stimulation in liver cirrhosis decreasing portal pressure without systemic effects.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Hennenberg M, Biecker E, Trebicka J, Jochem K, Zhou Q, Schmidt M, et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology. 2006;130:838–54.CrossRefPubMed Hennenberg M, Biecker E, Trebicka J, Jochem K, Zhou Q, Schmidt M, et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology. 2006;130:838–54.CrossRefPubMed
43.
Zurück zum Zitat Zhou H, Fang C, Zhang L, Deng Y, Wang M, Meng F. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, ameliorates hepatic fibrosis in rats with type 2 diabetes. Chin Med J. 2014;127:225–31.PubMed Zhou H, Fang C, Zhang L, Deng Y, Wang M, Meng F. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, ameliorates hepatic fibrosis in rats with type 2 diabetes. Chin Med J. 2014;127:225–31.PubMed
44.
Zurück zum Zitat Futakuchi A, Inoue T, Fujimoto T, Inoue-Mochita M, Kawai M, Tanihara H. The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts. Exp Eye Res. 2016;149:107–15.CrossRefPubMed Futakuchi A, Inoue T, Fujimoto T, Inoue-Mochita M, Kawai M, Tanihara H. The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts. Exp Eye Res. 2016;149:107–15.CrossRefPubMed
45.
Zurück zum Zitat Zhou Q, Hennenberg M, Trebicka J, Jochem K, Leifeld L, Biecker E, et al. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut. 2006;55:1296–305.CrossRefPubMedPubMedCentral Zhou Q, Hennenberg M, Trebicka J, Jochem K, Leifeld L, Biecker E, et al. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut. 2006;55:1296–305.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Klein S, Van Beuge MM, Granzow M, Beljaars L, Schierwagen R, Kilic S, et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. J Hepatol. 2012;57:1220–7.CrossRefPubMed Klein S, Van Beuge MM, Granzow M, Beljaars L, Schierwagen R, Kilic S, et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. J Hepatol. 2012;57:1220–7.CrossRefPubMed
47.
Zurück zum Zitat van Beuge MM, Prakash J, Lacombe M, Gosens R, Post E, Reker-Smit C, et al. Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice. J Pharmacol Exp Ther. 2011;337:628–35.CrossRefPubMed van Beuge MM, Prakash J, Lacombe M, Gosens R, Post E, Reker-Smit C, et al. Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice. J Pharmacol Exp Ther. 2011;337:628–35.CrossRefPubMed
48.
Zurück zum Zitat Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology. 2006;44:1039–46.CrossRefPubMed Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology. 2006;44:1039–46.CrossRefPubMed
49.
Zurück zum Zitat Pradella P, Bonetto S, Turchetto S, Uxa L, Comar C, Zorat F, et al. Platelet production and destruction in liver cirrhosis. J Hepatol. 2011;54:894–900.CrossRefPubMed Pradella P, Bonetto S, Turchetto S, Uxa L, Comar C, Zorat F, et al. Platelet production and destruction in liver cirrhosis. J Hepatol. 2011;54:894–900.CrossRefPubMed
50.
Zurück zum Zitat •Klein S, Herath CB, Schierwagen R, Grace J, Haltenhof T, Uschner FE, et al. Hemodynamic effects of the Non-peptidic angiotensin-(1–7) agonist AVE0991 in liver cirrhosis. PLoS ONE. 2015;10:e0138732. One of several studies indicating the beneficial effects of aspirin application for treatment of liver cirrhosis. •Klein S, Herath CB, Schierwagen R, Grace J, Haltenhof T, Uschner FE, et al. Hemodynamic effects of the Non-peptidic angiotensin-(1–7) agonist AVE0991 in liver cirrhosis. PLoS ONE. 2015;10:e0138732. One of several studies indicating the beneficial effects of aspirin application for treatment of liver cirrhosis.
51.
Zurück zum Zitat ••Yoshida S, Ikenaga N, Liu SB, Peng Z-W, Chung J, Sverdlov DY, et al. Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology. 2014;147:1378–92. An important work elucidating the role of platelets in hepatic stellate cell activation upon liver injury. ••Yoshida S, Ikenaga N, Liu SB, Peng Z-W, Chung J, Sverdlov DY, et al. Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology. 2014;147:1378–92. An important work elucidating the role of platelets in hepatic stellate cell activation upon liver injury.
52.
Zurück zum Zitat Jiang ZG, Feldbrügge L, Tapper EB, Popov Y, Ghaziani T, Afdhal N, et al. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. Aliment Pharmacol Ther. 2016;43:734–43.CrossRefPubMed Jiang ZG, Feldbrügge L, Tapper EB, Popov Y, Ghaziani T, Afdhal N, et al. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. Aliment Pharmacol Ther. 2016;43:734–43.CrossRefPubMed
53.
Zurück zum Zitat Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143:1253–60-4.CrossRefPubMed Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143:1253–60-4.CrossRefPubMed
54.
Zurück zum Zitat Yagüe S, Alvarez Arroyo V, Castilla A, González Pacheco FR, Llamas P, Caramelo C. Modulation of the effect of vascular endothelial growth factor on endothelial cells by heparin: critical role of nitric oxide-mediated mechanisms. J Nephrol. 2005;18:234–42.PubMed Yagüe S, Alvarez Arroyo V, Castilla A, González Pacheco FR, Llamas P, Caramelo C. Modulation of the effect of vascular endothelial growth factor on endothelial cells by heparin: critical role of nitric oxide-mediated mechanisms. J Nephrol. 2005;18:234–42.PubMed
55.
Zurück zum Zitat Tasatargil A, Ogutman C, Golbasi I, Karasu E, Dalaklioglu S. Comparison of the vasodilatory effect of nadroparin, enoxaparin, dalteparin, and unfractioned heparin in human internal mammary artery. J Cardiovasc Pharmacol. 2005;45:550–4.CrossRefPubMed Tasatargil A, Ogutman C, Golbasi I, Karasu E, Dalaklioglu S. Comparison of the vasodilatory effect of nadroparin, enoxaparin, dalteparin, and unfractioned heparin in human internal mammary artery. J Cardiovasc Pharmacol. 2005;45:550–4.CrossRefPubMed
56.
Zurück zum Zitat ••Cerini F, Vilaseca M, Lafoz E, García-Irigoyen O, García-Calderó H, Tripathi DM, et al. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol. 2016;64:834–42. Important work which introduces new treatment options to reduce portal pressure by anticoagulant therapy.CrossRefPubMed ••Cerini F, Vilaseca M, Lafoz E, García-Irigoyen O, García-Calderó H, Tripathi DM, et al. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol. 2016;64:834–42. Important work which introduces new treatment options to reduce portal pressure by anticoagulant therapy.CrossRefPubMed
57.
Zurück zum Zitat Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. 2016;61:1721–7.CrossRefPubMed Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. 2016;61:1721–7.CrossRefPubMed
58.
Zurück zum Zitat ••Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, et al. Obeticholic acid, a farnesoid-X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 2013. Important work which introduces new treatment options to reduce portal pressure by farnesoid-X receptor agonism ••Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, et al. Obeticholic acid, a farnesoid-X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 2013. Important work which introduces new treatment options to reduce portal pressure by farnesoid-X receptor agonism
59.
Zurück zum Zitat •Mookerjee RP, Mehta G, Balasubramaniyan V, Mohamed FEZ, Davies N, Sharma V, et al. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. J Hepatol. 2015;62:325–31. An important work elucidating how obeticholic acid restores endothelial function in liver cirrhosis. •Mookerjee RP, Mehta G, Balasubramaniyan V, Mohamed FEZ, Davies N, Sharma V, et al. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. J Hepatol. 2015;62:325–31. An important work elucidating how obeticholic acid restores endothelial function in liver cirrhosis.
60.
Zurück zum Zitat •Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Elst IV, et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Scientific Reports. 2016. Important work demonstrating fibrosis reduction additional to lowering portal pressure by obeticholic acid treatment. •Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Elst IV, et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Scientific Reports. 2016. Important work demonstrating fibrosis reduction additional to lowering portal pressure by obeticholic acid treatment.
61.
Zurück zum Zitat ••Verbeke L, Farre R, Verbinnen B, Covens K, Vanuytsel T, Verhaegen J, et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol. 2015;185:409–19. One of several important works showing that obeticholic acid treatment ameliorates bacterial translocation and thereby beneficially influences liver cirrhosis.CrossRefPubMed ••Verbeke L, Farre R, Verbinnen B, Covens K, Vanuytsel T, Verhaegen J, et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol. 2015;185:409–19. One of several important works showing that obeticholic acid treatment ameliorates bacterial translocation and thereby beneficially influences liver cirrhosis.CrossRefPubMed
62.
Zurück zum Zitat ••Úbeda M, Lario M, Muñoz L, Borrero M-J, Rodríguez-Serrano M, Sánchez-Díaz A-M, et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J Hepatol. 2016;64:1049–57. One of several important works showing that obeticholic acid treatment ameliorates bacterial translocation and thereby beneficially influences liver cirrhosis. ••Úbeda M, Lario M, Muñoz L, Borrero M-J, Rodríguez-Serrano M, Sánchez-Díaz A-M, et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J Hepatol. 2016;64:1049–57. One of several important works showing that obeticholic acid treatment ameliorates bacterial translocation and thereby beneficially influences liver cirrhosis.
63.
Zurück zum Zitat Laleman W, Trebicka J, Verbeke L. Evolving insights in the pathophysiology of complications of cirrhosis: The Farnesoid-X receptor (FXR) to the rescue? Hepatology. 2016 Laleman W, Trebicka J, Verbeke L. Evolving insights in the pathophysiology of complications of cirrhosis: The Farnesoid-X receptor (FXR) to the rescue? Hepatology. 2016
64.
Zurück zum Zitat Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Practice guidelines committee of the American association for the study of liver diseases, practice parameters committee of the American college of gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922–38.CrossRefPubMed Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Practice guidelines committee of the American association for the study of liver diseases, practice parameters committee of the American college of gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922–38.CrossRefPubMed
65.
Zurück zum Zitat Trebicka J, Hennenberg M, Schulze Pröbsting A, Laleman W, Klein S, Granzow M, et al. Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis. Hepatology. 2009;50:1924–35.CrossRefPubMed Trebicka J, Hennenberg M, Schulze Pröbsting A, Laleman W, Klein S, Granzow M, et al. Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis. Hepatology. 2009;50:1924–35.CrossRefPubMed
66.
Zurück zum Zitat Vasina V, Giannone F, Domenicali M, Latorre R, Berzigotti A, Caraceni P, et al. Portal hypertension and liver cirrhosis in rats: effect of the β3-adrenoceptor agonist SR58611A. Br J Pharmacol. 2012;167:1137–47.CrossRefPubMedPubMedCentral Vasina V, Giannone F, Domenicali M, Latorre R, Berzigotti A, Caraceni P, et al. Portal hypertension and liver cirrhosis in rats: effect of the β3-adrenoceptor agonist SR58611A. Br J Pharmacol. 2012;167:1137–47.CrossRefPubMedPubMedCentral
67.
Zurück zum Zitat Loureiro-Silva MR, Iwakiri Y, Abraldes JG, Haq O, Groszmann RJ. Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. J Hepatol. 2006;44:886–93.CrossRefPubMed Loureiro-Silva MR, Iwakiri Y, Abraldes JG, Haq O, Groszmann RJ. Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. J Hepatol. 2006;44:886–93.CrossRefPubMed
68.
Zurück zum Zitat Choi S-M, Shin J-H, Kim J-M, Lee C-H, Kang K-K, Ahn B-O, et al. Effect of udenafil on portal venous pressure and hepatic fibrosis in rats. Arzneimittelforschung. 2011;59:641–6.CrossRef Choi S-M, Shin J-H, Kim J-M, Lee C-H, Kang K-K, Ahn B-O, et al. Effect of udenafil on portal venous pressure and hepatic fibrosis in rats. Arzneimittelforschung. 2011;59:641–6.CrossRef
69.
Zurück zum Zitat Kreisel W, Deibert P, Kupcinskas L, Sumskiene J, Appenrodt B, Roth S, et al. The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. Dig Liver Dis. 2015;47:144–50.CrossRefPubMed Kreisel W, Deibert P, Kupcinskas L, Sumskiene J, Appenrodt B, Roth S, et al. The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. Dig Liver Dis. 2015;47:144–50.CrossRefPubMed
70.
Zurück zum Zitat Jiang JX, Chen X, Serizawa N, Szyndralewiez C, Page P, Schröder K, et al. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med. 2012;53:289–96.CrossRefPubMedPubMedCentral Jiang JX, Chen X, Serizawa N, Szyndralewiez C, Page P, Schröder K, et al. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med. 2012;53:289–96.CrossRefPubMedPubMedCentral
71.
Zurück zum Zitat García-Calderó H, Rodríguez-Vilarrupla A, Gracia-Sancho J, Diví M, Laviña B, Bosch J, et al. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol. 2011;54:660–5.CrossRefPubMed García-Calderó H, Rodríguez-Vilarrupla A, Gracia-Sancho J, Diví M, Laviña B, Bosch J, et al. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol. 2011;54:660–5.CrossRefPubMed
72.
Zurück zum Zitat Gonzalez-Paredes FJ, Hernández Mesa G, Morales Arraez D, Marcelino Reyes R, Abrante B, Diaz-Flores F, et al. Contribution of cyclooxygenase end products and oxidative stress to intrahepatic endothelial dysfunction in early non-alcoholic fatty liver disease. PLoS ONE. 2016;11:e0156650.CrossRefPubMedPubMedCentral Gonzalez-Paredes FJ, Hernández Mesa G, Morales Arraez D, Marcelino Reyes R, Abrante B, Diaz-Flores F, et al. Contribution of cyclooxygenase end products and oxidative stress to intrahepatic endothelial dysfunction in early non-alcoholic fatty liver disease. PLoS ONE. 2016;11:e0156650.CrossRefPubMedPubMedCentral
73.
Zurück zum Zitat Wu J, Saleh MA, Kirabo A, Itani HA, Montaniel KRC, Xiao L, et al. Immune activation caused by vascular oxidation promotes fibrosis and hypertension. J Clin Invest. 2016;126:50–67.CrossRefPubMed Wu J, Saleh MA, Kirabo A, Itani HA, Montaniel KRC, Xiao L, et al. Immune activation caused by vascular oxidation promotes fibrosis and hypertension. J Clin Invest. 2016;126:50–67.CrossRefPubMed
74.
Zurück zum Zitat De Gottardi A, Berzigotti A, Seijo S, D’Amico M, Thormann W, Abraldes JG, et al. Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. Am J Clin Nutr. 2012;96:584–90.CrossRefPubMed De Gottardi A, Berzigotti A, Seijo S, D’Amico M, Thormann W, Abraldes JG, et al. Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. Am J Clin Nutr. 2012;96:584–90.CrossRefPubMed
75.
Zurück zum Zitat ••Loffredo L, Del Ben M, Perri L, Carnevale R, Nocella C, Catasca E, et al. Effects of dark chocolate on NOX-2-generated oxidative stress in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2016;44:279–86. Important work demonstrating beneficial effects of controlled dark chocolate consumption in non-alcoholic steatohepatitis. ••Loffredo L, Del Ben M, Perri L, Carnevale R, Nocella C, Catasca E, et al. Effects of dark chocolate on NOX-2-generated oxidative stress in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2016;44:279–86. Important work demonstrating beneficial effects of controlled dark chocolate consumption in non-alcoholic steatohepatitis.
76.
Zurück zum Zitat ••Tripathi DM, Erice E, Lafoz E, García-Calderó H, Sarin SK, Bosch J, et al. Metformin reduces hepatic resistance and portal pressure in cirrhotic rats. Am J Physiol - Gastrointest Liver Physiol. 2015;309:G301–9. An important work introducing metformin as a therapeutic option for treatment of portal pressure in liver cirrhosis. ••Tripathi DM, Erice E, Lafoz E, García-Calderó H, Sarin SK, Bosch J, et al. Metformin reduces hepatic resistance and portal pressure in cirrhotic rats. Am J Physiol - Gastrointest Liver Physiol. 2015;309:G301–9. An important work introducing metformin as a therapeutic option for treatment of portal pressure in liver cirrhosis.
77.
Zurück zum Zitat Ma S-J, Zheng Y-X, Zhou P-C, Xiao Y-N, Tan H-Z. Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis. Oncotarget. 2016 Ma S-J, Zheng Y-X, Zhou P-C, Xiao Y-N, Tan H-Z. Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis. Oncotarget. 2016
78.
Zurück zum Zitat Doyle M-A, Singer J, Lee T, Muir M, Cooper C. Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. Trials. 2016;17:331.CrossRefPubMedPubMedCentral Doyle M-A, Singer J, Lee T, Muir M, Cooper C. Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. Trials. 2016;17:331.CrossRefPubMedPubMedCentral
79.
Zurück zum Zitat •Li T, Eheim AL, Klein S, Uschner FE, Smith AC, Brandon-Warner E, et al. Novel role of nuclear receptor rev-erbα in hepatic stellate cell activation: potential therapeutic target for liver injury. Hepatology. 2014;59:2383–96. Important study which offers a novel treatment target to reduce hepatic stellate cell activation in liver fibrosis.CrossRefPubMed •Li T, Eheim AL, Klein S, Uschner FE, Smith AC, Brandon-Warner E, et al. Novel role of nuclear receptor rev-erbα in hepatic stellate cell activation: potential therapeutic target for liver injury. Hepatology. 2014;59:2383–96. Important study which offers a novel treatment target to reduce hepatic stellate cell activation in liver fibrosis.CrossRefPubMed
Metadaten
Titel
Possible Treatment Strategies for Portal Hypertension in Liver Cirrhosis
verfasst von
Robert Schierwagen
Frank Erhard Uschner
Sabine Klein
Jonel Trebicka
Publikationsdatum
27.10.2016
Verlag
Springer US
Erschienen in
Current Hepatology Reports / Ausgabe 4/2016
Elektronische ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-016-0321-y

Weitere Artikel der Ausgabe 4/2016

Current Hepatology Reports 4/2016 Zur Ausgabe

Hepatitis B (JK Lim, Section Editor)

Future Therapy for HBV: Role of Cell Cycle Inhibitors

Hepatitis B (JK Lim, Section Editor)

Current Management of Hepatitis B in 2016

Hepatitis B (JK Lim, Section Editor)

The Cascade of Care in Chronic Hepatitis B

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Expanded Criteria for Resection: Are Current Guidelines Too Conservative?

Hepatitis C (J Ahn, Section Editor)

Hepatitis C and Hepatocellular Carcinoma

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.